Zenas BioPharma, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Zenas BioPharma is in Stage 3, the topping phase, now in week 2 (since Oct 9, 2026). It closed at $28.23, 34.6% below its 52-week high and above its 200-day average, which is falling.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. More about the company

$28.23

+0.53% today

$1.8B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ZBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-09-13 → 2026-10-22

S? 42w

S2 25w

S4 9w

2024-09-132026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S1 3w → S2 25w → S3 8w → S4 1w → S3 1w → S4 2w → S1 2w → S4 9w → S1 5w → S2 8w → S3 2w current

Total tracked: 109 weeks across 12 stage runs.

ZBIO among Biotechnology159th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…159	ZBIOZenas BioPharma, Inc.	Stage 3 · wk 2	61	−4.7%

vs 52W High

-34.6%

$15.20 lo$43.17 hi

34.6% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

14.4%

200 DMA: $24.68 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.58x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-4.7%

-7.1%

+52.7%

YTD

-18.2%

+8.5%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.58x

2026-10-21S3

Wk 2 · Vol 0.66x

2026-10-20S3

Wk 2 · Vol 0.78x

2026-10-19S3

Wk 2 · Vol 1.00x

2026-10-16S3

Wk 2 · Vol 0.95x

2026-10-15S3

Wk 1 · Vol 0.68x

2026-10-14S3

Wk 1 · Vol 0.61x

2026-10-13S3

Wk 1 · Vol 0.75x

2026-10-12S3

Wk 1 · Vol 0.87x

2026-10-09S32→3

Wk 1 · Vol 0.61x

2026-10-08S2

Wk 9 · Vol 0.80x

2026-10-07S2

Wk 9 · Vol 0.72x

Moving averages & range

50 DMA

$29.81

200 DMA

$24.68

52W High

$43.17

52W Low

$15.20

5D Low

$24.84

Resistance levels (recent highs)

20d High

$28.30

60d High

$33.77

120d High

$33.77

250d High

$43.17

Next resistance

+0.2%

to 20d High

ROE

-199.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 7.2

Zenas BioPharma: quick answers

What stage is Zenas BioPharma in?

As of Oct 22, 2026, Zenas BioPharma (ZBIO) is in Stage 3, the topping phase. It entered Stage 3 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Zenas BioPharma in an uptrend?

Its uptrend has stalled. Zenas BioPharma is in Stage 3, the topping phase that follows an advance. It trades 14.4% above its 200-day average, which is falling.

How far is Zenas BioPharma from its 52-week high?

Zenas BioPharma closed at $28.23 on Oct 22, 2026, 34.6% below its 52-week high of $43.17. Its 52-week low is $15.20.

How has Zenas BioPharma performed over the past year?

As of Oct 22, 2026, Zenas BioPharma is up 8.5% over the past year and down 18.2% so far in 2026.

Which sector and industry is Zenas BioPharma in?

Zenas BioPharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.